Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with u…
$15.73-2.96%
报价 2026-11-13
市值
$2.11B
EV
$1.93B
PE (TTM)
6.8x
预期 PE
–
52 周区间距高点 -15.5%
$13.95$18.62
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | $2.11B | -3.0% | – | 88.5% | 6.8x | 13.6x | – | |
| LKFTGalapagos N.V. Sponsored ADR | $2.23B | +0.1% | – | – | – | – | – | |
| IMNMImmunome, Inc. | $2.22B | +0.4% | -97.4% | -1,161.9% | – | – | – | |
| MRVIMaravai LifeSciences Holdings, Inc. | $2.14B | -1.8% | +16.0% | 34.6% | – | – | – | |
| ALMRAlamar Biosciences, Inc. | $2.14B | -3.0% | – | 59.3% | – | – | – | |
| BHVNBiohaven Ltd. | $2.09B | -1.8% | +55466.7% | 0% | – | – | – | |
| REPLReplimune Group, Inc. | $2.08B | -0.4% | +763.6% | 0% | – | – | – | |
| VERAVera Therapeutics, Inc. | $2.03B | -3.2% | +201.6% | 0% | – | – | – | |
| SEPNSepterna, Inc. | $2.03B | +1.8% | +149.0% | 99.4% | – | – | 16.4x | |
| 同行中位数 | – | – | +175.3% | 0% | – | – | 16.4x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。